At a glance
Effects
- Body weight reduction: Phase 2 obesity trials demonstrated clinically relevant body weight lowering of up to ~19%; the highest dose (4.8 mg) produced reductions roughly 5–7× greater than placebo, with over half of participants achieving ≥15% loss [6][7].
- MASH / liver-fat reduction: In a 48-week Phase 2 MASH trial, 43–62% of survodutide-treated participants met the primary endpoint (MASH resolution without worsening fibrosis) vs 22% with placebo, and 34–36% showed ≥1-stage fibrosis improvement [8].
- Appetite & satiety improvement: GLP-1R agonism activates satiety nuclei in the brain, suppressing food intake and reducing energy consumption [1][4].
- Increased energy expenditure: GCGR activation in the liver raises metabolic rate and promotes thermogenesis, adding a second lever for weight reduction beyond appetite suppression alone [4][3].
- Blood pressure reduction: A post-hoc analysis from the Phase 2 obesity trial found reductions in both systolic and diastolic blood pressure across doses, though a small number of participants experienced hypotension [8].
Dual GCGR/GLP-1R agonist peptide (investigational)
~1 week (albumin-binding C18 diacid enables once-weekly dosing) [5]
Subcutaneous injection (once weekly) [12]
Phase 3 (not approved; trials only) [2]
Boehringer Ingelheim & Zealand Pharma [3]
About Survodutide
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Survodutide (BI 456906) is an investigational dual glucagon/GLP-1 receptor (GCGR/GLP-1R) co-agonist peptide in Phase 3 clinical development for obesity and metabolic dysfunction-associated steatohepatitis (MASH) [1]. It is not yet approved by any regulatory authority and is currently available only within clinical trials [2].
How it works
Survodutide simultaneously activates two distinct receptors: GLP-1R and GCGR [3]. GLP-1 receptor agonism in the brain suppresses appetite, increases satiety, and slows gastric emptying, while glucagon receptor agonism in the liver increases energy expenditure via thermogenesis and promotes direct hepatic fat reduction [1][4]. A fatty acid chain (C18 diacid) in the peptide's scaffold binds to albumin, extending the half-life sufficiently to allow once-weekly subcutaneous dosing [5]. This dual mechanism sets survodutide apart from GLP-1 monoagonists (e.g. semaglutide) and GLP-1/GIP dual agonists (e.g. tirzepatide) by adding glucagon's thermogenic and lipolytic properties while GLP-1 activity mitigates glucagon's hyperglycaemic effects [3].
Risks & side effects
Most important: Gastrointestinal adverse events — primarily nausea, vomiting, and diarrhea — are the dominant safety concern, occurring in up to 56–75% of participants at higher doses and driving a 24.6% discontinuation rate in the Phase 2 obesity trial [9][10]. These effects are most intense during dose escalation and generally subside during the maintenance phase; Phase 3 trials use a slower, flexible titration schedule to improve tolerability [9].
Common
Serious
- Acute pancreatitis risk (class effect of GLP-1 agonists; baseline lipase evaluation recommended; watch for persistent upper abdominal pain) [11][12]
- Gallbladder disease / cholelithiasis (rapid weight loss increases gallstone risk) [10][12]
- Hypoglycaemia risk (elevated when combined with insulin or sulfonylureas due to glucagon suppression of counter-regulation) [12]
- Elevated heart rate (~3.2–3.5 bpm increase seen in Phase 3 data, consistent with GLP-1/glucagon class effects) [13]
- Hypotension (observed in a small number of participants in Phase 2; antihypertensives may need adjustment) [8]
Rare
- Thyroid C-cell tumour / medullary thyroid carcinoma (theoretical class risk based on GLP-1 agonism; no confirmed cases in trials to date) [11][14]
- Pancreatic cancer (theoretical; actively adjudicated in ongoing Phase 3 safety monitoring; no confirmed cases in Phase 2/3 data so far) [13][14]
- Severe hypersensitivity / anaphylaxis (pre-specified adverse event of special interest in SYNCHRONIZE trials) [12]
- Drug-induced liver injury (pre-specified adverse event of special interest; clinical relevance in MASH populations under evaluation) [12]
Safety & harm reduction
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2) — class contraindication based on GLP-1 receptor agonism [11]
- History of pancreatitis — class warning; survodutide has not been studied in this population [12]
- Known hypersensitivity to survodutide or any peptide excipient [12]
- Concurrent use of other incretin-based therapies (GLP-1 agonists, GIP agonists) — do not combine [10]
- Not for use in type 1 diabetes without specialist supervision — glucagon agonism may disrupt counter-regulation
- Baseline and periodic lipase/amylase — pancreatitis surveillance [11]
- Calcitonin and thyroid monitoring (per Phase 3 SYNCHRONIZE safety protocol) [12]
- Blood pressure — monitor and adjust antihypertensives as needed during dose escalation [8]
- Heart rate — modest increase (~3 bpm) expected; monitor in patients with baseline tachycardia [13]
- Liver enzymes and kidney function — prespecified laboratory safety parameters in Phase 3 trials [12]
- Blood glucose — especially important in patients with T2D or on insulin/sulfonylurea [10]
- Body composition monitoring recommended to differentiate fat loss from lean mass loss during rapid weight reduction [8]
- Insulin / sulfonylureas — increased hypoglycaemia risk; dose reduction may be required [10]
- Antihypertensive medications — blood-pressure-lowering effects may be additive; monitor for hypotension [8]
- Other GLP-1 agonists or incretin therapies — avoid combination [10]
- Oral medications with narrow therapeutic windows — gastric emptying delay may alter absorption; timing should be considered
- Use a gradual dose-escalation schedule to minimise GI adverse events; Phase 3 SYNCHRONIZE trials uptitrate to 3.6 mg or 6.0 mg with dose flexibility [12]
- Administer subcutaneously in the abdomen, thigh, or upper arm; rotate injection sites
- Educate on GI side-effect management: small meals, avoiding high-fat foods, staying hydrated during escalation [9]
- Survodutide is investigational and NOT commercially available — only accessible through authorised clinical trials [2]
Dosage context
Survodutide is investigational and has no approved prescribing dose. Phase 2 obesity trials studied once-weekly subcutaneous doses ranging from 0.3 mg to 4.8 mg using structured escalation over 20 weeks [15]. Phase 3 SYNCHRONIZE trials are evaluating uptitration to 3.6 mg and 6.0 mg once weekly with a flexible schedule [12]. These figures are clinical-trial protocols, not prescriptions or endorsed dosing ranges. Do not self-administer outside a supervised clinical setting.
Sources
- 1.PMC – Survodutide acts through circumventricular organs (brain mechanism)
- 2.Boehringer Ingelheim – Survodutide MASH Phase 2 top-line results
- 3.PatSnap – Survodutide GLP-1/glucagon dual agonist Phase III overview
- 4.PMC – Mechanisms of action of GLP-1 and dual GIP/GLP-1 receptor agonists
- 5.ScienceDirect – Perspectives in weight control in diabetes: Survodutide (half-life / albumin binding)
- 6.ScienceDirect – Phase 2 dose-finding trial: survodutide for obesity (Lancet)
- 7.BodySpec – Survodutide guide: weight loss & MASH trial data
- 8.FindHonestCare – Survodutide side effects & safety profile (Phase 2 data)
- 9.ThePeptideList – Survodutide side effects 2026
- 10.PeptideInitiative – Survodutide safety, contraindications & dosing context
- 11.AJMC – Survodutide Phase 3 SYNCHRONIZE-1 data (cardiovascular, pancreatic, thyroid safety)
- 12.PMC – SYNCHRONIZE-1 and -2 Phase 3 trial rationale and design
- 13.JACC Heart Failure – Survodutide SYNCHRONIZE cardiovascular outcomes trial design
- 14.Cardiology Advisor – Survodutide SYNCHRONIZE-1 Phase 3 efficacy (weight loss, safety)
- 15.PMC – Survodutide dose–response in T2D (Phase 2 dose-escalation schemes)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.